吉西他滨联合顺铂治疗中晚期非小细胞肺癌临床近期疗效观察  

The treatment with Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-small cell lung cancer

作　　者：舒守宏[1] 方平[1] 

机构地区：[1]安徽省铜陵市人民医院呼吸内科,安徽铜陵244000

出　　处：《中国医药导报》2009年第21期70-72,共3页China Medical Herald

摘　　要：目的:观察国产吉西他滨(GEM,泽菲)联合顺铂(PDD)组成的GP方案治疗中晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法:42例经病理或细胞学证实的中晚期非小细胞肺癌患者,采用GP方案化疗,GEM1000mg/m2第1天、第8天静滴,PDD80mg/m2第1天静滴,21d为1个周期,使用2～4个周期。结果:42例中,完全缓解(CR)2例(4.76%),部分缓解(PR)17例(40.48%),稳定(SD)14例(33.33%),进展(PD)9例(21.42%),客观有效率(RR=CR+PR)为45.24%(19/42)。毒副作用主要表现为血白细胞、血小板下降,恶心呕吐等,但均可耐受。结论:吉西他滨联合顺铂治疗中晚期非小细胞肺癌有较好的疗效,毒副作用可耐受,值得临床推广应用。Objective： To observe the therapeutic effect and side effect of Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-small cell lung cancer （NSCLC）. Methods： 42 patients with advanced NSCLC enrolled in allotted to the study. The patients were treated with GP regiment, GEM 1 000 mg/m2, dl and d8 intravenous infusion. PDD 80 mg/m2 dl intravenous infusion. 21 days for one cycle,all patients received 2-4 cycles therapies. Results： In 42 cases, CR 2 cases （4.76%）,PR 17 cases （40.48%）,SD 14 cases （33.33%）,PD 9 cases （21.42%）,RR（CR＋PR） was 45.24% （19/42）. The main side effects were leucopoenia,thrombocytopenia,gastro-intestinal reaction. Conclusion： Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer have better efficacy, side effects can be tolerated, it is worth clinical application

关 键 词：非小细胞肺癌 吉西他滨 顺铂 化疗 

分 类 号：R73[医药卫生—肿瘤]